Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort

被引：0
|
作者：
Servitja, Sonia
Torres, Elisabet
Prieto-Alhambra, Dani
Rodriguez-Sanz, Maria
Martinez-Garcia, Maria
Gonzalez Maeso, Iria
Diez-Perez, Adolf
Nogues, Xavi
Tusquets, Ignacio
机构：
[1] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
[2] Hosp del Mar, Dept Internal Med, URFOA, Barcelona, Spain
[3] Univ Oxford, Botnar Res Ctr, NDORMS, Oxford, England
[4] IMIM Parc Salut Mar, URFOA, Barcelona, Spain
[5] Hosp del Mar, Med Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
579
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen
    Oyan, Basak
    MEDICAL HYPOTHESES, 2011, 77 (06) : 1028 - 1030
  • [42] Prevention of Bone Loss in Breast Cancer Survivors on Aromatase Inhibitors: Results of the REBBeCA II Trial
    Greenspan, Susan
    Perera, Subashan
    Vujevich, Karen
    van Londen, Gisberta
    Brufsky, Adam
    Lembersky, Barry
    Puhalla, Shannon
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [43] Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
    Brufsky, Adam M.
    CLINICAL BREAST CANCER, 2007, 8 : S22 - S34
  • [44] TRABECULAR AND CORTICAL BONE HEALTH IN POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS FOR EARLY BREAST CANCER TREATMENT: THE B - A B L E PROSPECTIVE COHORT STUDY
    Nogues Solan, X.
    Rodriguez, R.
    Rodriguez-Sanz, M.
    Winzenrieth, R.
    Humbert, L.
    Pineda-Moncusi, M.
    Servitja, S.
    Garcia-Giralt, N.
    Martos, T.
    Tusquets, I.
    Martinez-Garcia, M.
    Rodriguez Morera, R.
    Dies Perez, A.
    Albanell, J.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S455 - S456
  • [45] Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
    Lester, James E.
    Dodwell, David
    Purohit, Omprakash P.
    Gutcher, Sandra A.
    Ellis, Susan P.
    Thorpe, Ruth
    Horsman, Janet M.
    Brown, Janet E.
    Hannon, Rosemary A.
    Coleman, Robert E.
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6336 - 6342
  • [46] Relation of genes in estrogen and vitamin D signaling to bone mineral density loss in aromatase inhibitors treatment
    Servitja, Sonia
    Rodriguez-Sanz, Maria
    Garcia-Giralt, Natalia
    Torres, Elisabet
    Prieto-Alhambra, Dani
    Mellibovsky, Leonardo
    Tusquets, Ignacio
    Diez-Perez, Adolf
    Nogues, Xavi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Adherence to guidelines for bone health in a predominantly Hispanic cohort of breast cancer patients receiving aromatase inhibitors
    Bright, Tamis M.
    Mcalice, Meghan K.
    Escriba-Omar, Abelardo
    Gaur, Sumit
    Philipovskiy, Alexander V.
    CANCER RESEARCH, 2020, 80 (04)
  • [48] Prevalence of bone loss among nonmetastatic breast cancer patients treated with aromatase inhibitors in the United States
    Pirolli, M.
    Hernandez, R. K.
    Reich, A.
    Liede, A.
    CANCER RESEARCH, 2016, 76
  • [49] Aromatase Inhibitor Adjuvant Chemotherapy of Breast Cancer Results in Cancer Therapy Induced Bone Loss
    Renee Z. Rinaldi
    Current Osteoporosis Reports, 2013, 11 : 61 - 64
  • [50] A COHORT STUDY OF RADIOGRAPHIC ALVEOLAR BONE LOSS DURING ADOLESCENCE
    AASS, AM
    TOLLEFSEN, T
    GJERMO, P
    JOURNAL OF CLINICAL PERIODONTOLOGY, 1994, 21 (02) : 133 - 138
12345